About TBI

Traumatic brain injury (TBI) affects approx. 15 million individuals annually worldwide and is one of the leading causes of death. It is associated with high rates of hospitalization, mortality and disability. TBI occurs when a sudden trauma causes damage to the brain. TBI can result from sudden and violent hits to the head, or when an object penetrates the skull, injuring brain tissue.

Treatment options

Current knowledge of today indicates that modern therapy of brain injuries should optimally target various pathological mechanisms simultaneously rather than focus on a single therapeutic target.

The general management of TBI includes:
  • Initial emergency treatment for patient stabilization, including surgery
  • Acute treatment aimed at minimizing secondary injury, including mechanical ventilation, control of intracranial pressure, cerebral perfusion pressure and edema, as well as sedative-, seizure- and antiepileptic treatment
  • Rehabilitation therapy
  • Pharmacological therapy, such as Cerebrolysin®
Cerebrolysin® is an add-on therapy to standard care and should be initiated as soon as possible and continued throughout the rehabilitation phase. Clinical data confirm benefits.

Such a multimodal approach is most effective for assuring optimal recovery after brain injuries.

Clinical Efficacy in TBI

By stimulating natural neuroprotective and neurorecovery processes, Cerebrolysin® can alleviate short-and long-term consequences of TBI while providing an excellent safety profile.
Learn more

FAQ

Any further questions? Then you can find here some frequently asked questions with detailed answers.
Learn more

Source

Levin, Harvey S.; Shum, David; Chan, Raymond CK (Hg.). understanding traumatic brain injury: current research and future directions. Oxford University Press, USA, 2014
Maas, Andrew IR; Roozenbeek, Bob; Manley, Geoffrey T. Clinical trials in traumatic brain injury: past experience and current developments. neurotherapeutics, 2010, 7. Jg., nr. 1, S. 115-126.
Rogalewski A., Schneider A., Ringelstein B., Schäbitz W. R., Toward a multimodal neuroprotective Treatment of Stroke, Stroke 2006; 37: 1129-11

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.